Merck Announces Samsung Bioepis receives approval of Renfelxis (infliximab), a biosimilar of Remicade, in Korea

Samsung Bioepis’ second immunology biosimilar approved, to be commercialized under partnership with Merck

Samsung Bioepis’ Renflexis is indicated in Korea for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis in adult patients (age 18 years and older). Merck plans to launch Renfexis in South Korea in the first half of 2016.

“Merck is committed to delivering on the promise of biosimilars and we look forward to bringing Renflexis forward to help meet the needs of physicians, patients and healthcare systems,” said Dora Bibila, general manager, Merck Biosimilars.

Merck’s commercial launch of Renflexis in Korea will include comprehensive education and support services for healthcare professionals, patients and their caregivers, including biosimilars education, disease education, and reimbursement and access support.